Sufentanil Sublingual Tablet System: from rationale of use to clinical practice

Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11891-11899. doi: 10.26355/eurrev_202011_23847.


The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Pain / drug therapy
  • Administration, Sublingual
  • Analgesia, Patient-Controlled / instrumentation*
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / therapeutic use*
  • Humans
  • Pain Management / instrumentation*
  • Pain, Postoperative / drug therapy*
  • Practice Guidelines as Topic*
  • Sufentanil / administration & dosage
  • Sufentanil / therapeutic use*
  • Tablets


  • Analgesics, Opioid
  • Tablets
  • Sufentanil